Switching from ligand to receptor anti‐calcitonin gene‐related peptide ( CGRP ) antibodies or vice versa in non‐responders: A controlled cohort study
European Journal of Neurology · 2025
DOI: 10.1111/ene.16542 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Nancy van Veelen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and purpose Limited options exist for migraine prevention after stopping anti‐calcitonin gene‐related peptide monoclonal antibodies. A systematic review examining the benefits of switching between different classes (ligand vs. receptor monoclonal antibody) is essential, alongside well‐designed real‐world studies.
Methods
In this cohort study 67 patients were included, who discontinued their first treatment with erenumab or fremanezumab. Patients ( n = 31) switched to another monoclonal antibody class within 3 months, whilst those in the control group ( n = 36) received standard care. Allocation to either group relied largely on the availability of alternative monoclonal antibody treatments, introducing pseudo‐random allocation. Changes in monthly migraine days were compared between groups 3 months post‐discontinuation of the first monoclonal antibody or initiation of a different monoclonal antibody class. A multivariate regression model was conducted that accounted for potential confounding factors.
Results
The groups were comparable at baseline and poor treatment response was the main reason for treatment discontinuation of the first monoclonal antibody. The switching cohort experienced a reduction of 3.9 monthly migraine days (95% confidence interval −6.4, −1.3, p = 0.004) compared with the control group.
Conclusion
Transitioning to a different anti‐calcitonin gene‐related peptide monoclonal class yields reduction in monthly migraine days compared to returning to standard care for patients with inadequate initial treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.
ORCID-Profile: Nancy van Veelen, Britt W H van der Arend
Zitieren
APA
van Veelen, N., van der Arend, B. W. H., Hiele, E., van Zwet, E. W., & Terwindt, G. M. (2025). Switching from ligand to receptor anti‐calcitonin gene‐related peptide ( CGRP ) antibodies or vice versa in non‐responders: A controlled cohort study. European Journal of Neurology. https://doi.org/10.1111/ene.16542
Vancouver
van Veelen N, van der Arend BWH, Hiele E, van Zwet EW, Terwindt GM. Switching from ligand to receptor anti‐calcitonin gene‐related peptide ( CGRP ) antibodies or vice versa in non‐responders: A controlled cohort study. European Journal of Neurology. 2025. doi:10.1111/ene.16542
BibTeX
@article{vanVeelen2025,
author = {van Veelen, Nancy and van der Arend, Britt W H and Hiele, E and van Zwet, E W and Terwindt, Gisela M},
title = {Switching from ligand to receptor anti‐calcitonin gene‐related peptide ( CGRP ) antibodies or vice versa in non‐responders: A controlled cohort study},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.16542}
}
EUVIMED